{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":52,"n_cols":5,"rows_kept":52,"merged":[[1,1,1,4]],"flags":["formulas_cached_only"]}
[]
[null,"Supplementary Table 1. Baseline patient characteristics in advanced esophageal and gastric cancers"]
[null,"Characteristics","ICIs first  (n=174)","Chemotherapy first (n=160)","P-value"]
[null,"Demographic characteristics"]
[null,"Age at ICI initiation (years)","67 (27-89)","67 (25-85)",0.497]
[null,"Sex"]
[null,"Male","136 (78.2%)","111 (69.4%)",0.068]
[null,"Female","38 (21.8%)","49 (30.6%)"]
[null,"ECOG PS at ICI initiation"]
[null,"0-1","101 (58.0%)","109 (68.1%)",0.057]
[null,2,"73 (42.0%)","51 (31.9%)"]
[null,"DM"]
[null,"Yes","21 (12.1%)","12 (7.5%)",0.162]
[null,"No","153 (87.9%)","148 (92.5%)"]
[null,"Tumor variables"]
[null,"Tumor type"]
[null,"Esophageal cancer","63 (36.2%)","71 (44.4%)",0.128]
[null,"Gastric cancer","111 (63.8%)","89 (55.6%)"]
[null,"Distant metastasis"]
[null,"Yes","134 (77.0%)","117 (73.1%)",0.412]
[null,"No","40 (23.0%)","43 (26.9%)"]
[null,"PD-L1 expression (CPS)"]
[null,">1%","56 (32.2%)","42 (26.3%)",0.325]
[null,"<1%","59 (33.9%)","58 (36.3%)"]
[null,"Missing","59 (33.9%)","60 (37.5%)"]
[null,"ICI treatment variables"]
[null,"Antibiotic use"]
[null,"Yes","23 (13.2%)","20 (12.5%)",0.845]
[null,"No","151 (86.8%)","140 (87.5%)"]
[null,"Corticosteroids use"]
[null,"Yes","72 (41.4%)","57 (35.6%)",0.281]
[null,"No","102 (58.6%)","103 (64.4%)"]
[null,"ICI treatment line"]
[null,"Firstline","131 (75.3%)","119 (74.4%)",0.977]
[null,"Secondline","36 (20.7%)","34 (21.3%)"]
[null,"3rd, or 4th-line","7 (4.0%)","7 (4.4%)"]
[null,"Administration time of ICI"]
[null,"Morning","131 (75.3%)","111 (69.4%)",0.227]
[null,"Afternoon","43 (24.7%)","49 (30.6%)"]
[null,"Interval between chemotherapy and ICI"]
[null,"On the same day","99 (56.9%)","72 (45.0%)",{"v":0.03,"d":"0.030"}]
[null,"At least one day apart","75 (43.1%)","88 (55.0%)"]
[null,"Regimen"]
[null,"Fluorouracil","29 (16.7%)","21 (13.1%)",{"v":0.34,"d":"0.340"}]
[null,"Paclitaxel","33 (19.0%)","24 (15.0%)"]
[null,"Combination therapy","112 (64.4%)","115 (71.9%)"]
[null,"Laboratory variables"]
[null,"ALC (*10^9/L)","1.17 (0.37-5.15)","1.20 (0.19-18.20)",0.104]
[null,"AMC (*10^9/L)","0.45 (0.01-1.89)","0.46 (0.01-1.92)",0.367]
[null,"ANC (*10^9/L)","3.51 (0.80-17.32)","3.60 (1.02-15.50)",{"v":0.11,"d":"0.110"}]
[null,"HGB (g/L)","113 (54-167)","115 (62-166)",0.098]
[null,"CEA (ng/mL)","3.14 (0.26-1000.00)","2.44 (0.22-1000.00)",0.423]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}